Zensun Completed Chinese Phase II Clinical Study of rhNRG-1
2009-05-06
Zensun accomplished Chinese phase II clinical trial of rhNRG-1—Zensun’s proprietary anti-heart failure drug.
During the past two years, Zensun conducted randomized, double-Blind, multi-center, placebo-controlled phase II clinical studies in over 30 hospitals nationwide. The initial statistics show that the heart function was improved effectively with rhNRG-1 treatment.
In May 21st, 2009, Zensun held press conference in Zhangjiang, Shanghai and claimed phase II clinical study report in China and Australia to the media worldwide.
更多动态
Zensun is Collaborating with The Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. to Conduct a Preclinical Study of Neucardin® (recombinant human Neuregulin-1) for The Treatment of Schwannomas
ZENSUN ANNOUNCES THE INVESTIGATION OF NEUCARDIN FOR CHRONIC HEART FAILURE RECEIVES FAST TRACK DESIGNATION FROM THE US FDA
An International Multi-center Phase III Clinical Trial of Recombinant Human Neuregulin-1 is going to